Costa Rica vs Europe (WHO region): New cases tested for RR-/MDR-TB
Costa Rica
100.0%
in 2024
Europe (WHO region)
88.0%
in 2024
Costa Rica rank
1st
Europe (WHO region) rank
3rd
New cases tested for RR-/MDR-TB over time
- Costa Rica
- Europe (WHO region)
How they compare
Costa Rica currently reports 100.0% against 88.0% in Europe (WHO region), a difference of 12.0%.
That makes Costa Rica's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 5 times across 15 shared years of data; in 2005 it was Europe (WHO region) ahead.
Costa Rica ranks 1st and Europe (WHO region) ranks 3rd of 192 countries.
Europe (WHO region) has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Costa Rica | Europe (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.2% | 40.0% | 39.8% | Europe (WHO region) |
| 2010s | 52.1% | 84.1% | 32.0% | Europe (WHO region) |
| 2020s | 70.8% | 90.8% | 20.0% | Europe (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher new cases tested for rr-/mdr-tb, Costa Rica or Europe (WHO region)?
- Costa Rica, at 100.0% against 88.0% in Europe (WHO region) as of 2024.
- What is the difference in new cases tested for rr-/mdr-tb between Costa Rica and Europe (WHO region)?
- 12.0%, with Costa Rica ahead.
- How many years of comparable data are there for Costa Rica and Europe (WHO region)?
- 15 years are reported by both, from 2005 to 2024.
- How do Costa Rica and Europe (WHO region) rank globally for new cases tested for rr-/mdr-tb?
- Costa Rica ranks 1st and Europe (WHO region) ranks 3rd of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as New cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.